These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 21220792)

  • 1. [Lights off? Neurobiological and pharmacological aspects of the melatonergic-serotonergic synergism].
    Sumegi A; Somoskovi C
    Neuropsychopharmacol Hung; 2010 Dec; 12(4):469-75. PubMed ID: 21220792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Agomelatine: new drug. Adverse effects and no proven efficacy.
    Prescrire Int; 2009 Dec; 18(104):241-5. PubMed ID: 20020562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Melatonergic drugs in clinical practice.
    Hardeland R; Poeggeler B; Srinivasan V; Trakht I; Pandi-Perumal SR; Cardinali DP
    Arzneimittelforschung; 2008; 58(1):1-10. PubMed ID: 18368944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Agomelatine as chronopsychopharmaceutics restoring circadian rhythms and enhancing resilience to stress: a wishfull thinking or an innovative strategy for superior management of depression?
    Jakovljević M
    Psychiatr Danub; 2011 Mar; 23(1):2-9. PubMed ID: 21448091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Melatoninergic antidepressant valdoxan].
    Arushanian ÉB
    Eksp Klin Farmakol; 2011; 74(7):41-5. PubMed ID: 21894769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Agomelatine in depressive disorders: its novel mechanisms of action.
    Srinivasan V; Zakaria R; Othman Z; Lauterbach EC; Acuña-Castroviejo D
    J Neuropsychiatry Clin Neurosci; 2012; 24(3):290-308. PubMed ID: 23037643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Melatonin and melatonergic drugs on sleep: possible mechanisms of action.
    Srinivasan V; Pandi-Perumal SR; Trahkt I; Spence DW; Poeggeler B; Hardeland R; Cardinali DP
    Int J Neurosci; 2009; 119(6):821-46. PubMed ID: 19326288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathophysiology of depression: role of sleep and the melatonergic system.
    Srinivasan V; Pandi-Perumal SR; Trakht I; Spence DW; Hardeland R; Poeggeler B; Cardinali DP
    Psychiatry Res; 2009 Feb; 165(3):201-14. PubMed ID: 19181389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical experiences with agomelatine. The inner ear has to be synchronized again].
    MMW Fortschr Med; 2010 Mar; 152(10):46-7. PubMed ID: 20380235
    [No Abstract]   [Full Text] [Related]  

  • 10. Addressing circadian rhythm disturbances in depressed patients.
    Lam RW
    J Psychopharmacol; 2008 Sep; 22(7 Suppl):13-8. PubMed ID: 18753278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging targets for the pharmacological treatment of depression: focus on melatonergic system.
    Catena-Dell'Osso M; Marazziti D; Rotella F; Bellantuono C
    Curr Med Chem; 2012; 19(3):428-37. PubMed ID: 22335516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Depression--sequelae of disturbed circadian rhythm. Rapid onset of effect supports treatment success].
    MMW Fortschr Med; 2010 Oct; 152(40):48-9. PubMed ID: 21049646
    [No Abstract]   [Full Text] [Related]  

  • 13. Beyond the monoaminergic hypothesis: agomelatine, a new antidepressant with an innovative mechanism of action.
    Kasper S; Hamon M
    World J Biol Psychiatry; 2009; 10(2):117-26. PubMed ID: 19255935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Modern approaches to the synchronization of circadian rhythms in treatment of depression].
    Barylnik JB; Filippova NV; Trayber LV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(11):124-8. PubMed ID: 25629135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disturbances of diurnal phase markers, behavior, and clock genes in a rat model of depression; modulatory effects of agomelatine treatment.
    Højgaard K; Christiansen SL; Bouzinova EV; Wiborg O
    Psychopharmacology (Berl); 2018 Mar; 235(3):627-640. PubMed ID: 29151193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Agomelatine: the first "melatoninergic" antidepressant].
    Bánki MC
    Neuropsychopharmacol Hung; 2006 Oct; 8(3):105-12. PubMed ID: 17211046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Depression: possible etiology: circadian dysregulation].
    MMW Fortschr Med; 2012 Jan; 154(1):82-3. PubMed ID: 22642014
    [No Abstract]   [Full Text] [Related]  

  • 18. Bidirectional communication between sleep and circadian rhythms and its implications for depression: lessons from agomelatine.
    Pandi-Perumal SR; Moscovitch A; Srinivasan V; Spence DW; Cardinali DP; Brown GM
    Prog Neurobiol; 2009 Aug; 88(4):264-71. PubMed ID: 19454302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Agomelatine, the first melatonergic antidepressant: discovery, characterization and development.
    de Bodinat C; Guardiola-Lemaitre B; Mocaër E; Renard P; Muñoz C; Millan MJ
    Nat Rev Drug Discov; 2010 Aug; 9(8):628-42. PubMed ID: 20577266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic potential of agomelatine in epilepsy and epileptic complications.
    Vimala PV; Bhutada PS; Patel FR
    Med Hypotheses; 2014 Jan; 82(1):105-10. PubMed ID: 24314750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.